Ionis Pharmaceuticals Inc
IONS
Market Cap$5.95B
Close$
$-20.03
147.9% downside
Current Fair Value
147.9% downsideOvervalued by 147.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.95 Billion |
|---|---|
| Enterprise Value | $4.89 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.56 |
| Beta | 0.45 |
| Outstanding Shares | 145,750,000 |
| Avg 30 Day Volume | 964,660 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -16.24 |
|---|---|
| PEG | 19.72 |
| Price to Sales | 8.37 |
| Price to Book Ratio | 20.92 |
| Enterprise Value to Revenue | 6.21 |
| Enterprise Value to EBIT | -13.83 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 3.29 |
Revenue Sources
No data
ESG Score
No data
About Ionis Pharmaceuticals Inc
817 employees
CEO: Brett Monia Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...